Pharmaceuticals News and Research

RSS

Patrick K. Donnelly announces official launch of Aptiv Solutions

Chairman and CEO Patrick K. Donnelly today announced the official launch of Aptiv Solutions, a global biopharmaceutical and medical device development services company.

1 Jun 2011

FDA approves APP Pharmaceuticals' Piperacillin and Tazobactam for Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration to market Piperacillin and Tazobactam for Injection, the number one prescribed intravenous antibiotic in the U.S. APP will launch the product immediately.

1 Jun 2011

E64d reduces Aβ levels and improves memory function in brains of Alzheimer's disease mice

Researchers at the University of California, San Diego, the Medical University of South Carolina and American Life Science Pharmaceuticals of San Diego have demonstrated that oral administration of a cysteine protease inhibitor, E64d, not only reduces the build-up of β-amyloid in the brains of animal models for Alzheimer's disease, but also results in a substantial improvement in memory deficit.

1 Jun 2011

CrystalGenomics begins enrollment in CG100649 Phase 2b osteoarthritis study

CrystalGenomics, Inc. and CG Pharmaceuticals, Inc., a biopharmaceutical company with 3 clinical stage candidates, has announced that the first patient has been enrolled for a Phase 2b clinical study of CG100649, CrystalGenomics' clinical stage novel NSAID candidate, in patients with knee or hip osteoarthritis.

1 Jun 2011

Ampio commences new anti-inflammatory agent Phase 1B trial in osteoarthritis

Ampio Pharmaceuticals, Inc. announced today that it received ethics board approval for a Phase 1B clinical trial in Australia of its biologic anti-inflammatory agent, Ampion.

1 Jun 2011

Centocor Ortho Biotech, AVEO sign license deal to develop, commercialize RON-targeted antibodies

AVEO Pharmaceuticals, Inc. today announced it has entered into an exclusive license agreement with Centocor Ortho Biotech Inc. for the worldwide development and commercialization of AVEO's internally-discovered antibodies targeting the RON receptor.

1 Jun 2011

Enrollment complete in BioSante's LibiGel Phase III cardiovascular and breast cancer safety study

BioSante Pharmaceuticals, Inc., today announced completion of enrollment in its ongoing LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product.

31 May 2011

First Edition: May 31, 2011

Today's headlines include articles on the federal efforts to improve hospital quality, the politics of Medicare and the move by some GOP governors to set up health exchanges.

31 May 2011

Defiante, Dyax expand KALBITOR partnership to treat hereditary angioedema

Dyax Corp. and Defiante Farmaceutica S.A., an affiliate of the pharmaceutical group Sigma-Tau, announced today an expansion of their strategic partnership for KALBITOR in the treatment of hereditary angioedema and other therapeutic indications to include development and commercialization rights in Latin America, excluding Mexico and the Caribbean, Taiwan, Singapore and South Korea.

31 May 2011

Radiant to expand consumer products testing capabilities

Radiant Research, Inc. today announced that it is expanding its consumer products testing capabilities through creation of a new division of Radiant Research devoted to consumer trial conduct.

31 May 2011

Ashland agrees to acquire ISP

Ashland Inc. and International Specialty Products Inc. today announced that Ashland has agreed to acquire privately owned ISP, a global specialty chemical manufacturer of innovative functional ingredients and technologies.

31 May 2011

AIS releases stainless steel HMI color LCD monitors for pharma industries

American Industrial Systems, Inc. is an ISO 9001:2008 certified supplier and manufacturer of 15" to 20" industrial LCD monitor with stainless steel front bezels and touch screens, designed for use in the food, beverage, pharmaceutical and tobacco industries for operator control and monitoring.

31 May 2011

Takeda, Affymax submit peginesatide NDA to FDA for treatment of anemia linked with chronic renal failure

Affymax, Inc. and Takeda Pharmaceutical Company Limited today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for the investigational agent peginesatide for the treatment of anemia associated with chronic renal failure in adult patients on dialysis.

31 May 2011

YM announces updates on nimotuzumab clinical development program

YM BioSciences Inc., today provided an update on the development program for nimotuzumab, including its North American clinical program for nimotuzumab, manufacturing scale-up activities, and data presentations anticipated for nimotuzumab at the 2011 Annual Meeting of the American Society of Clinical Oncology.

31 May 2011

Heptares, AstraZeneca partner to discover and develop new GPCR drug targets

AstraZeneca and Heptares Therapeutics today announced they have entered a four-year collaboration focused on the potential discovery and development of new medicines targeting G-protein coupled receptors.

31 May 2011

Novartis employees to do volunteer work for non-profit groups during 15th annual Community Partnership Day

Some 200 employees of Novartis Pharmaceuticals Canada Inc. will again this year be helping out with cleaning, painting and various other chores and activities at 15 Montreal-area organizations as part of their 15th annual Community Partnership Day, during which they leave their offices for the day to do volunteer work for non-profit groups. It is part of a global effort by Novartis employees that involves 20,000 employees in 55 countries.

30 May 2011

National Pharmacovigilance Programme to increase awareness about benefits of adverse event reporting

Adverse Drug Reactions (ADRs) are the sixth global leading cause of death among hospitalised patients and the incidence of serious ADRs in hospitalised patients is 6.7 per cent.

From IQPC Ltd 30 May 2011

New position paper examines benefits of actual, virtual natural environments on human health

A new position paper by researchers at the European Centre for the Environment and Human Health and the University of Birmingham has compared the benefits of interaction with actual and virtual natural environments and concluded that the development of accurate simulations are likely to be beneficial to those who cannot interact with nature because of infirmity or other limitations: but virtual worlds are not a substitute for the real thing.

30 May 2011

Optimer receives FDA approval for Dificid tablets to treat C. difficile-associated diarrhea

The U.S. Food and Drug Administration today approved Dificid tablets for the treatment of Clostridium difficile-associated diarrhea.

30 May 2011

Efficacy of Abbott cholesterol drug in question

A latest study has found that using medication to raise good cholesterol while lowering the bad does NOT translate into fewer adverse cardiovascular events like heart attacks and strokes. The study was revealed Thursday by the National Institutes of Health and it found that high dosages of Abbott Laboratories' Niaspan failed to prevent heart attacks and boosted the likelihood of a stroke when combined with the popular generic cholesterol pill Simvastatin, also known under the brand name Zocor.

29 May 2011

Pharmaceuticals News and Research

Patrick K. Donnelly announces official launch of Aptiv Solutions

FDA approves APP Pharmaceuticals' Piperacillin and Tazobactam for Injection

E64d reduces Aβ levels and improves memory function in brains of Alzheimer's disease mice

CrystalGenomics begins enrollment in CG100649 Phase 2b osteoarthritis study

Ampio commences new anti-inflammatory agent Phase 1B trial in osteoarthritis

Centocor Ortho Biotech, AVEO sign license deal to develop, commercialize RON-targeted antibodies

Enrollment complete in BioSante's LibiGel Phase III cardiovascular and breast cancer safety study

First Edition: May 31, 2011

Defiante, Dyax expand KALBITOR partnership to treat hereditary angioedema

Radiant to expand consumer products testing capabilities

Ashland agrees to acquire ISP

AIS releases stainless steel HMI color LCD monitors for pharma industries

Takeda, Affymax submit peginesatide NDA to FDA for treatment of anemia linked with chronic renal failure

YM announces updates on nimotuzumab clinical development program

Heptares, AstraZeneca partner to discover and develop new GPCR drug targets

Novartis employees to do volunteer work for non-profit groups during 15th annual Community Partnership Day

National Pharmacovigilance Programme to increase awareness about benefits of adverse event reporting

New position paper examines benefits of actual, virtual natural environments on human health

Optimer receives FDA approval for Dificid tablets to treat C. difficile-associated diarrhea

Efficacy of Abbott cholesterol drug in question

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence